🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Dr. Reddy’s Labs launches Posaconazole Delayed-Release Tablets in US

bySrinath
April 20, 2022
Total
0
Shares
0
0
0

Dr. Reddy’s Laboratories said that it has launched Posaconazole Delayed-Release Tablets, 100 mg, a triazole antifungal drug, in the US market.

Posaconazole Delayed-Release Tablets is the therapeutic generic equivalent to NOXAFIL (posaconazole) Delayed-Release Tablets, 100 mg, which has approval from the US Food and Drug Administration.

Dr. Reddy's Labs launches Posaconazole Delayed-Release Tablets in US
Dr. Reddy’s Labs launches Posaconazole Delayed-Release Tablets in US. Photo courtesy of Karthikndr/Wikimedia Commons.

According to IQVIA, the NOXAFIL brand and generic had sales of nearly $140.8 million MAT in the US for the most recent 12 months ending in February 2022.

Dr. Reddy’s Posaconazole Delayed-Release Tablets have been launched in 100 mg strength in bottle count sizes of 60.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ironwood Pharmaceuticals (Nasdaq: IRWD) names Tammi Gaskins CEO as LINZESS profits rise

Ironwood Pharmaceuticals has appointed Chief Commercial Officer Tammi Gaskins to succeed Tom McCourt as Chief Executive Officer from January 2027. The succession follows a major 2025 workforce reduction and arrives after sharply stronger LINZESS economics restored profitability, leaving Gaskins to balance cash generation with the late-stage development of apraglutide.
byPallavi Madhiraju